Navigation Links
Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
Date:5/21/2013

LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today.  The detailed results of the vote for the election of directors are set out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. Michael Pearson232,521,8255,174,857Robert N. Power235,168,8502,527,832Norma A. Provencio237,125,741570,941Howard B. Schiller221,521,55916,175,123Lloyd M. Segal236,082,5291,614,153Katharine Stevenson234,501,1463,195,536At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2014 annual meeting of shareholders; and approved the continuance of the Company from the Canada Business Corporations Act to the British Columbia Business Corporations Act.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
4. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
5. Valeant Pharmaceuticals Provides Efinconazole Update
6. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
7. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
8. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
9. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
10. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
11. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017 Mederi Therapeutics today ... studies, representing 2468 patients who received  Stretta Therapy  ... entitled, " Systematic Review and Meta-Analysis of Controlled ... for Treatment of Gastroesophageal Reflux Disease ", was published ... Ronnie Fass , MD, head of the Esophageal ...
(Date:2/27/2017)...   Royal Philips (NYSE: ... health technology, today announced 510(k) clearance from the ... its ElastQ Imaging capability, further expanding the functionalities ... Imaging enables simultaneous imaging of tissue and assessment ... diagnosis of various liver conditions. With ElastQ Imaging, ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, 2017 ... device company focused on developing cerebral embolic protection ... members of the FDA,s Circulatory System Devices Panel ... of the need for cerebral protection following transcatheter ... statements shared by this FDA panel support the ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... cognitive rehabilitation, according to a study released today at the 1st Pan American ... programs are proven to be effective in improving cognitive function in PD patients. ...
(Date:2/25/2017)... Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total ... sliders to easily refine their color range. With color spectrum tools users can visually ...
(Date:2/24/2017)... TX (PRWEB) , ... February 24, 2017 , ... ... offering promotions on tooth replacement options at his office, Antoine Dental Center. Currently, ... implants for $18,499. Some restrictions may apply, but patients can learn more about ...
(Date:2/24/2017)... NJ (PRWEB) , ... February 24, 2017 , ... ... that provides business development, education, networking and recognition opportunities as well as advocacy ... Bell Works in Holmdel, NJ on February 23. The Council's Innovation Forecast ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
Breaking Medicine News(10 mins):